Tags

Type your tag names separated by a space and hit enter

Polymorphisms in CYP1A1 and breast carcinoma risk in a population-based case-control study of Chinese women.
Cancer. 2005 Jun 01; 103(11):2228-35.C

Abstract

BACKGROUND

Cytochrome P450 1A1 (CYP1A1) is involved in the 2-hydroxylation of estrogen, the hormone that plays a critical role in the etiology of breast carcinoma.

METHODS

The authors evaluated common polymorphisms in the CYP1A1 gene in relation to breast carcinoma risk in a large population-based case-control study among Chinese women, the Shanghai Breast Cancer Study. Because the CYP1A1*3 and CYP1A1*4 alleles were not detected in the study population, analyses were performed for CYP1A1*2A (T-->C transition in the 3' noncoding region) and CYP1A1*2C (A-->G transition in exon 7, resulting in a substitution of Val for Ile) in 1134 patients with breast carcinoma and 1227 controls.

RESULTS

The frequencies of the variant allele were 38.3% and 38.8% among cases and controls (P = 0.91), respectively, for the CYP1A1*2A polymorphism, and 23.1% and 24.8% (P = 0.26) for the CYP1A1*2C polymorphism. Homozygosity for both variant alleles in these 2 polymorphic sites (CYP1A1*2B) was associated with a borderline significant odds ratio (OR) of 0.71 (95% confidence interval [CI], 0.47-1.06). The reduced risk was more pronounced among postmenopausal women with long duration (> 30 yrs) of menstruation (OR = 0.43; 95% CI, 0.19-0.99) or among women with a low waist-to-hip ratio (OR = 0.52; 95% CI, 0.28-0.94).

CONCLUSIONS

Results from the current study suggest that homozygosity for the CYP1A1*2A and CYP1A1*2C alleles in the CYP1A1 gene may be associated with a reduced risk for breast carcinoma, particularly among lean women with long-term endogenous estrogen exposure.

Authors+Show Affiliations

Department of Medicine, Center for Health Services Research, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

15856430

Citation

Boyapati, Sonia M., et al. "Polymorphisms in CYP1A1 and Breast Carcinoma Risk in a Population-based Case-control Study of Chinese Women." Cancer, vol. 103, no. 11, 2005, pp. 2228-35.
Boyapati SM, Shu XO, Gao YT, et al. Polymorphisms in CYP1A1 and breast carcinoma risk in a population-based case-control study of Chinese women. Cancer. 2005;103(11):2228-35.
Boyapati, S. M., Shu, X. O., Gao, Y. T., Cai, Q., Jin, F., & Zheng, W. (2005). Polymorphisms in CYP1A1 and breast carcinoma risk in a population-based case-control study of Chinese women. Cancer, 103(11), 2228-35.
Boyapati SM, et al. Polymorphisms in CYP1A1 and Breast Carcinoma Risk in a Population-based Case-control Study of Chinese Women. Cancer. 2005 Jun 1;103(11):2228-35. PubMed PMID: 15856430.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Polymorphisms in CYP1A1 and breast carcinoma risk in a population-based case-control study of Chinese women. AU - Boyapati,Sonia M, AU - Shu,Xiao Ou, AU - Gao,Yu-Tang, AU - Cai,Qiuyin, AU - Jin,Fan, AU - Zheng,Wei, PY - 2005/4/28/pubmed PY - 2005/7/22/medline PY - 2005/4/28/entrez SP - 2228 EP - 35 JF - Cancer JO - Cancer VL - 103 IS - 11 N2 - BACKGROUND: Cytochrome P450 1A1 (CYP1A1) is involved in the 2-hydroxylation of estrogen, the hormone that plays a critical role in the etiology of breast carcinoma. METHODS: The authors evaluated common polymorphisms in the CYP1A1 gene in relation to breast carcinoma risk in a large population-based case-control study among Chinese women, the Shanghai Breast Cancer Study. Because the CYP1A1*3 and CYP1A1*4 alleles were not detected in the study population, analyses were performed for CYP1A1*2A (T-->C transition in the 3' noncoding region) and CYP1A1*2C (A-->G transition in exon 7, resulting in a substitution of Val for Ile) in 1134 patients with breast carcinoma and 1227 controls. RESULTS: The frequencies of the variant allele were 38.3% and 38.8% among cases and controls (P = 0.91), respectively, for the CYP1A1*2A polymorphism, and 23.1% and 24.8% (P = 0.26) for the CYP1A1*2C polymorphism. Homozygosity for both variant alleles in these 2 polymorphic sites (CYP1A1*2B) was associated with a borderline significant odds ratio (OR) of 0.71 (95% confidence interval [CI], 0.47-1.06). The reduced risk was more pronounced among postmenopausal women with long duration (> 30 yrs) of menstruation (OR = 0.43; 95% CI, 0.19-0.99) or among women with a low waist-to-hip ratio (OR = 0.52; 95% CI, 0.28-0.94). CONCLUSIONS: Results from the current study suggest that homozygosity for the CYP1A1*2A and CYP1A1*2C alleles in the CYP1A1 gene may be associated with a reduced risk for breast carcinoma, particularly among lean women with long-term endogenous estrogen exposure. SN - 0008-543X UR - https://www.unboundmedicine.com/medline/citation/15856430/Polymorphisms_in_CYP1A1_and_breast_carcinoma_risk_in_a_population_based_case_control_study_of_Chinese_women_ L2 - https://doi.org/10.1002/cncr.21056 DB - PRIME DP - Unbound Medicine ER -